Antiviral mechanism and visualization of the interferon induced protein Mx1

Designed, broadly protective antibodies directed against influenza B.

Development and validation of an oral influenza A vaccine based on M2e-expressing bacteriophages

Development of a robust expression system for stable soluble influenza neuraminidase

Development of a RSV vaccine based on virus like particles that display short fragments of viral surface proteins

Development of intrabody-expressing influenza virus vectors to discover new pro- and antiviral host factors

Evolution of the influenza A virus quasi species in the naive and the immune host

Fcgamma receptor-mediated anti-viral therapy

Generation of potent, broadly betacoronavirus neutralizing antibody constructs

Identification and characterization of viral and host factors involved in the pathogenesis of influenza A virus

Identification and characterization of viral and host factors that are involved in the pathogenicity of influenza A virus

Identification of influenza A virus quasi-species evolution in the immune host using quantitative next gen sequence analysis

Identification of the immunologic mechanism of action of an M2e-based influenza vaccine

Innate and adaptive immune responses to influenza virus infection under conditions of infection-permissive immunity

Investigation of the mechanism of immune protection evoked by a novel RSV vaccine candidate based on the ectodomain of the small hydrophobic protein.

In vivo analysis of the infection dynamics of influenza and human RSV in naive and immunized mice with the use of recombinant reporter viruses.

Mx interacting proteins

New antivirals against human parainfluenza virus

New antivirals against RSV

New antiviral strategy against human parainfluenzavirus

New molecular intervention technology in airway disease caused by allergy or infection

Next generation sequencing to analyze the quasispecies evolution of influenza A virus in the immune host

Novel Respiratory Syncytial Vaccine

Phosphoproteome analysis of host-RSV interactions

Phosphoproteome analysis of host-RSV interactions

Prepared for SARS-CoV-3: advancing our understanding of SARS coronavirus antigenic and pathogenic evolution

Prophylaxis of at risks persons with an ultrapotent SARS-CoV-2-neutralizing antibody

Protection against influenza A virus infection and modulation of antigen presentation by matrix protein 2-specific antibodies.

Single domain antibodies that neutralize SARS-CoV-2

Stabilisation and high expression systems of influenza neuraminidase.

Study of the anti-viral function against influenza proteins of Mx

The SH protein of human RSV: a possible proton channel that can be targeted by a vaccine.

Understanding and exploiting glycosylation in immunotherapy.

A nanobody-based anti-inflammatory treatment against pathogen-induced chronic lung inflammation

A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases.

A nanobody-based anti-inflammatory treatment against Pseudomonas aeruginosa-induced inflammation in chronic lung diseases

Chlorea toxin as a delivery system for peptide CTL epitopes

Flow imaging microscope for advanced analysis of biopharmaceuticals and biological samples

Healthcare applications of targeted protein aggregation

Improving monoclonal antibody production in glycosylationhumanized Pichia pastoris strains

mRNA Lipid nanoparticles co-loaded with alpha-Galactosylceramide as a universal influenza vaccine platform

Respiratory Syncitial Virus immunology and molecular virology

Stimulated emission depletion microscopy (STED): Nanoscopy for innovative research in the life sciences

Swine as an intermediate host for potentially pandemic avian influenza viruses: unravelling host species barriers

Enabling antibody prophylaxis of the elderly and vulnerable using yeast-based biotechnology.